Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: Development, in vitro characterization and antioxidant activity

Ourique, Aline Ferreira; Chaves, Paula dos Santos; Souto, Gabriele Dadalt; Pohlmann, Adriana Raffin; Guterres, Sílvia Stanisçuaski; Beck, Ruy Carlos Ruver

doi:10.1016/j.ejps.2014.09.017

Cited by 42 publications

(28 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this context, powders having different granulometries could be administered by means of a dry powder inhaler with an appropriate drug delivery along the respiratory tract (28). The behavior of post-dry redispersion is evaluated by the wet diffraction technique to demonstrate that the powders from a dispersion time are able to recover their nanometric characteristics (29).…”

Section: Development and Characterization Of The Nanocapsule Spray-drmentioning

confidence: 99%

Dry-Powder of Chitosan-Coated Lipid-Core Nanocapsules Containing Dapsone: Development, Laser Diffraction Characterization and Analytical Quantification

Cé¹,

Jornada²,

Marchi³

et al. 2019

Drug Anal. Res.

View full text Add to dashboard Cite

Analytical techniques are critical for ensuring physical and chemical stability of a drug both for assessing the stability of drug molecules and for quantifying and identifying the drug content in products. We proposed the development of dry-powders of lipid-core nanocapsules containing dapsone and coated with chitosan, as well as, the analytical quantification of dapsone in dry-powders with 1% and 2% (m/v) of leucine by high-performance liquid chromatography (HPLC). Size is the most relevant physicochemical property of nanoparticulated drug delivery systems. In this context, our results demonstrated that during the powders redispersion in water, could be observed that the mean particle diameters (DAP-LNC-CS-L1 and DAP-LNC-CS-L2) decreased with redispersion times increase. The spray-drying of the lipid-core nanocapsule formulations showed yields ranging from 58 ± 1.0 % (DAP-LNC-CS-L1) to 61 ± 1.5 % (DAP-LNC-CS-L2) indicating an efficient drying process. In this context, the analytical quantifications of dapsone in the dry powders of nanocapsules by HPLC showed that the dapsone content ranged from 92 ± 1.4% (DAP-LNC-CS-L2) to 95 ± 0.8% (DAP-LNC-CS-L1). Can be concluded that spray-drying process of DAP-LNC-CS-L1 and DAP-LNC-CS-L2 formulations showed an efficient aqueous dispersion of nanocapsule powders and the analytical quantification of dapsone in spray-dryed powders were higher than 90%.

show abstract

Section: Development and Characterization Of The Nanocapsule Spray-drmentioning

confidence: 99%

Dry-Powder of Chitosan-Coated Lipid-Core Nanocapsules Containing Dapsone: Development, Laser Diffraction Characterization and Analytical Quantification

Cé¹,

Jornada²,

Marchi³

et al. 2019

Drug Anal. Res.

View full text Add to dashboard Cite

show abstract

“…For example, the spray drying of drugs in liposome formulations has been shown to be appropriate for manufacturing particles with a small aerodynamic size (i.e. high FPF), and it was presumed that the rehydration of liposomes may take place following the deposition of the powder in the aqueous environment of the lung [ 41 , 42 , 43 ]. An approach to gene therapy was introduced by spray drying a lactose solution incorporating lipid-polycation-pDNA, resulting in an enhanced transfection compared to formulation prior to spray drying [ 44 ].…”

Section: Devices Used For the Pulmonary Delivery Of Liposomesmentioning

confidence: 99%

Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications

et al. 2016

View full text Add to dashboard Cite

This is a critical review on research conducted in the field of pulmonary delivery of liposomes. Issues relating to the mechanism of nebulisation and liposome composition were appraised and correlated with literature reports of liposome formulations used in clinical trials to understand the role of liposome size and composition on therapeutic outcome. A major highlight was liposome inhalation for the treatment of lung cancers. Many in vivo studies that explored the potential of liposomes as anticancer carrier systems were evaluated, including animal studies and clinical trials. Liposomes can entrap anticancer drugs and localise their action in the lung following pulmonary delivery. The safety of inhaled liposomes incorporating anticancer drugs depends on the anticancer agent used and the amount of drug delivered to the target cancer in the lung. The difficulty of efficient targeting of liposomal anticancer aerosols to the cancerous tissues within the lung may result in low doses reaching the target site. Overall,following the success of liposomes as inhalable carriers in the treatment of lung infections, it is expected that more focus from research and development will be given to designing inhalable liposome carriers for the treatment of other lung diseases, including pulmonary cancers. The successful development of anticancer liposomes for inhalation may depend on the future development of effective aerosolisation devices and better targeted liposomes to maximise the benefit of therapy and reduce the potential for local and systemic adverse effects.

show abstract

“…In isolated lungs and in vivo, it was shown that NAC reduces cell apoptosis of lung tissue (Chiang et al 2012), while liposomal NAC had better pharmacokinetics and efficacy than free NAC, especially under systemic oxidative stress (Xu et al 2012). Recently, there have been some studies on liposomal NAC in ALI, but only as an inhalant (Ourique et al 2014), or as a means to prevent the development of ALI (Mitsopoulos et al 2008). There have been no experimental studies considering the therapeutic efficacy of liposomal NAC in aspiration lung injury.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of liposomal dosage forms and hyperosmolar salines in experimental pharmacotherapy of acute lung injury

Kulikov¹,

Ageev²,

Marochkina³

et al. 2019

RRP

View full text Add to dashboard Cite

Citation: Kulikov OA, Ageev VP, Marochkina EE, Dolgacheva IS, Minayeva OV, Inchina VI (2018) Efficacy of liposomal dosage forms and hyperosmolar salines in experimental pharmacotherapy of acute lung injury. Research Results in Pharmacology 5(2): 23-41. https://doi. AbstractIntroduction: Hypertonic sodium chloride solutions and liposomal drugs with pulmotropic effect are of great interest for the treatment of acute lung injury (ALI). The results of the studies on the efficacy of hypertonic solutions and liposomes in ALI treatment are currently controversial. Materials and methods:For the experiment, liposomes with dexamethasone, N-acetylcysteine (NAC), aprotinin and dye Cyanine-7 (Cy-7) were obtained. A liposome analysis was performed by means of spectrophotometry. ALI was modeled in rats by the administration of the damaging agents into the trachea. The experimental agents were injected once intravenously after the modeling of ALI. For experimental therapy used liposomal agents, 7.5% hypertonic saline (HS) and HyperHAES solutions in the respective groups. The efficacy of the therapy was assessed by the survival of animals, functional indicators of the cardiovascular and respiratory systems, and by the lung-body ratio. The biodistribution of liposomes after intravenous administration was investigated in mice through using a fluorescent dye Cy-7. The biodistribution of liposomes with Cy-7 was assessed using bioimaging according to the fluorescence intensity of internal organs (lungs, liver, and kidneys) and blood, expressed as dye concentration according to the calibration dependence of dye concentrarion on fluorescence intensity. Results and discussion:All the studied liposomal drugs were effective for the pharmacological correction of ALI. Hypertonic solutions, unlike liposomal drugs, were less likely to prevent the development of pulmonary edema. All the studied therapeutic agents increased the survival rate of the laboratory animals with ALI. The most effective experimental agent was liposomal dexamethasone. The use of drugs in form of simple liposomes with average diameter of 350 nm provided for a higher concentration of the drug in the lungs within the first 40 minutes after intravenous administration. Conclusion:Intravenous administration of liposomal forms is promising for the pharmacotherapy of acute lung injury.

show abstract

Redispersible liposomal-N-acetylcysteine powder for pulmonary administration: Development, in vitro characterization and antioxidant activity

Cited by 42 publications

References 62 publications

Dry-Powder of Chitosan-Coated Lipid-Core Nanocapsules Containing Dapsone: Development, Laser Diffraction Characterization and Analytical Quantification

Dry-Powder of Chitosan-Coated Lipid-Core Nanocapsules Containing Dapsone: Development, Laser Diffraction Characterization and Analytical Quantification

Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications

Efficacy of liposomal dosage forms and hyperosmolar salines in experimental pharmacotherapy of acute lung injury

Contact Info

Product

Resources

About